BURLINGAME, Calif.,
June 21, 2024 /PRNewswire/ -- The
global dyspareunia treatment market is estimated to be valued at
USD 754.1 Mn in 2024 and is expected
to reach USD 1,035.4 Mn by 2031,
exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024
to 2031, as highlighted in a new report published by Coherent
Market Insights. Dyspareunia, also known as genito-pelvic
pain/penetration disorder (GPPDJ, is a highly prevalent sexual
dysfunction that affects both physical and emotional well-being of
women. It has been estimated that approximately 12% of women
worldwide experience symptoms of dyspareunia. The high prevalence
of this disorder and lack of effective treatment options available
has created significant unmet medical needs.
Request Sample Copy of this Report:
https://www.coherentmarketinsights.com/insight/request-sample/6885
Market Dynamics:
The growth of the dyspareunia treatment market is majorly driven
by the increasing research and development activities for
developing novel therapies to treat dyspareunia. For instance, in
August 2019, researchers from
University of Florence,
Florence, Italy tested the use of
fractional carbon dioxide laser therapy for the treatment of
provoked vestibulodynia, which is a form of dyspareunia. The
results showed that carbon dioxide laser therapy reduced pain
during intercourse and increased sexual function and satisfaction.
Moreover, growing adoption of minimally invasive procedures for the
treatment of dyspareunia is also expected to aid in the market
growth over the forecast period. For instance, procedures such as
pulsed radiofrequency treatment, botox injection, and
radiofrequency coagulation are gaining traction owing to benefits
such as less pain, faster recovery time, and lower risks of
complication associated with them.
Dyspareunia Treatment Market Report Coverage
Report
Coverage
|
Details
|
Market Revenue in
2024
|
$754.1 million
|
Estimated Value by
2031
|
$1,035.4 million
|
Growth
Rate
|
Poised to grow at a
CAGR of 4.6%
|
Historical
Data
|
2019–2023
|
Forecast
Period
|
2024–2031
|
Forecast
Units
|
Value (USD
Million/Billion)
|
Report
Coverage
|
Revenue Forecast,
Competitive Landscape, Growth Factors, and Trends
|
Segments
Covered
|
By Drug Type, By Route
of Administration, By Distribution Channel
|
Geographies
Covered
|
North America, Europe,
Asia Pacific, and Rest of World
|
Growth
Drivers
|
• Increasing Awareness
and Openness about Sexual Health Issues
• Increasing Product
Launches by Key Market Players
|
Restraints &
Challenges
|
• Social Stigma and
Cultural Taboos
• Lack of Awareness in
Developing Regions
|
Market Trends:
Growing adoption of hormonal therapy is one of the key trends
being witnessed in the dyspareunia treatment market. Estrogen plays
an important role in regulation of vaginal tissues, and low
estrogen levels caused due to menopause can cause thinning,
dryness, and inflammations of vaginal tissues leading to pain
during intercourse. Therefore, local estrogen therapies through
creams, rings, and tablets are widely used for management of
dyspareunia caused due to low estrogen levels. Furthermore,
increasing preference for alternative therapies for the treatment
of dyspareunia is another major trend in the market. Alternative
therapies including acupuncture, massage, capsaicin cream, alpha
blockers, and nerve blocks are gaining acceptance owing to lesser
side effects and advantage of combination therapies.
Immediate Delivery Available | Buy This Premium Research
Report:
https://www.coherentmarketinsights.com/insight/buy-now/6885
The selective estrogen receptor modulators (SERMs) segment is
expected to dominate the drug type segment owing to the minimal
side effects associated with its usage. SERMs help reduce
dyspareunia and vaginal dryness in postmenopausal women by blocking
the effects of estrogen in tissues like the breast and uterine
lining while having estrogenic effects in other tissues like bone
and vagina. Drugs like ospemifene help relieve pain during sexual
intercourse and treat moderate to severe dyspareunia through
selective action at estrogen receptors in the vagina and other
tissues.
Within the route of administration segment, oral route is
anticipated to hold the major share due to higher patient
adherence. The oral route provides instant relief through easy
intake of tablets and capsules. Drugs taken orally get absorbed
quickly through the gastrointestinal tract into the bloodstream and
provide relief from symptoms within a short period. The
non-invasive nature and convenience of oral drugs boost their
demand over other administration routes.
Key Market Takeaways:
The global dyspareunia treatment market is anticipated to
witness a CAGR of 4.6% during the forecast period 2024-2031, driven
by the rising prevalence of postmenopausal symptoms and associated
painful sex.
On the basis of drug type, selective estrogen receptor
modulators segment is expected to hold a dominant position owing to
the minimal side effects of SERM drugs.
On the basis of route of administration, oral segment is
expected to hold a dominant position over the forecast period due
to higher patient adherence resulting from easy intake.
By region, North America is
expected to hold a dominant position over the forecast period due
to the increasing research on women's health issues and growing
healthcare expenditure in the region.
Key players operating in the dyspareunia treatment market
include Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG
Pharmaceutical Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD,
Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk
A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd,
Cosette Pharmaceuticals, Inc., and Mundipharma International. These
players are involved in developing new treatment options and
launching generic versions of branded drugs to strengthen their
market position.
Recent Developments:
In December 2023, DARE BIOSCIENCE,
INC.M announced that the U.S. Food and Drug Administration has
cleared an investigational new drug application for DARE-VVA1, a
tamoxifen currently being developed as a non-hormone therapy to be
administrated intravaginally in patients with moderate to serve
dyspareunia, which often present in menopausal patients with vulvar
and vaginal atrophy.
In June 2023, Cosette
Pharmaceutical, Inc, announced the acquisition of Endorecherche.,
Inc.
Ask for Customization:
https://www.coherentmarketinsights.com/insight/request-customization/6885
Detailed Segmentation-
By Drug Type:
- Selective Estrogen Receptor Modulators
- Estrogens (Miscellaneous Vaginal Agents)
- Corticosteroids
- Antibiotics
- Others
By Route of Administration:
- Oral
- Vaginal Inserts
- Others
By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
- Others
By Region:
North America:
Latin America:
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe:
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East:
- GCC Countries
- Israel
- Rest of Middle East
Africa:
- South Africa
- North Africa
- Central Africa
Browse More Insights:
Vaginal Fungi Infections Treatment Market: The global
vaginal fungi infections treatment market is estimated to be
valued at US$ 987.2 million in 2020 and is
expected to exhibit a CAGR of 5.3% during the forecast
period (2020-2027).
Acute Vulvovaginal Candidiasis Treatment Market; The
global acute vulvovaginal candidiasis treatment market is
estimated to be valued at US$ 308.0 Mn in 2020 and is
expected to exhibit a CAGR of 3.0% over the forecast
period (2020-2027).
Candidiasis Market: The global candidiasis
market size was valued at US$ 873.8
million in 2017, and is expected to exhibit a CAGR of 4.6%
over the forecast period (2018–2026).
About Author:
Ravina Pandya, Content Writer,
has a strong foothold in the market research industry. She
specializes in writing well-researched articles from different
industries, including food and beverages,information and
technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
About Us:
Coherent Market Insights is a global market intelligence and
consulting organization that provides syndicated research reports,
customized research reports, and consulting services. We are known
for our actionable insights and authentic reports in various
domains including aerospace and defense, agriculture, food and
beverages, automotive, chemicals and materials, and virtually all
domains and an exhaustive list of sub-domains under the sun. We
create value for clients through our highly reliable and accurate
reports. We are also committed in playing a leading role in
offering insights in various sectors post-COVID-19 and continue to
deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
Logo :
https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/dyspareunia-treatment-market-to-hit-1-035-4-million-by-2031--at-a-cagr-of-4-6-says-coherent-market-insights-302178976.html